Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment von Schwenkglenks, Matthias, Jackisch, Christian, Constenla, Manuel, Kerger, Joseph N, Paridaens, Robert, Auerbach, Leo, Bosly, André, Pettengell, Ruth, Szucs, Thomas D, Leonard, Robert

Volltext

Phase II trial of oxaliplatin and 5-FU in patients (pts) with platinum-resistant recurrent (PRR) ovarian carcinoma (OVCA) von Kerger, Joseph N., Lebrun, Fabienne, Gil, Thierry, Gombos, Andrea, Ridoine, Amina, Bustin, Fanny, D'hondt, Veronique

Volltext

An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, v... von Hollebecque, Antoine, Meyer, Tim, Moore, Kathleen N., Machiels, Jean-Pascal H., De Greve, Jacques, López-Picazo, José María, Oaknin, Ana, Kerger, Joseph N., Boni, Valentina, Evans, T.R. Jeffry, Kristeleit, Rebecca Sophie, Rao, Shangbang, Soumaoro, Ibrahima, Cao, Z. Alexander, Topalian, Suzanne Louise

Volltext

Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final result... von Guigay, Joel, Fayette, Jerome, Dillies, Anne-Francoise, Sire, Christian, Kerger, Joseph N., Tennevet, Isabelle, Machiels, Jean-Pascal H., Zanetta, Sylvie, Pointreau, Yoann, Bozec Le Moal, Laurence, Brugel Ribere, Lydia, Henry, Stefanie, Temam, Stéphane

Volltext

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial von Naumann, R Wendel, Hollebecque, Antoine, Meyer, Tim, Devlin, Michael-John, Oaknin, Ana, Kerger, Joseph, López-Picazo, Jose M, Machiels, Jean-Pascal, Delord, Jean-Pierre, Evans, Thomas R J, Boni, Valentina, Calvo, Emiliano, Topalian, Suzanne L, Chen, Tian, Soumaoro, Ibrahima, Li, Bin, Gu, Junchen, Zwirtes, Ricardo, Moore, Kathleen N

Volltext

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial von Taieb, Julien, Prof, Tabernero, Josep, Prof, Mini, Enrico, Prof, Subtil, Fabien, PhD, Folprecht, Gunnar, MD, Van Laethem, Jean-Luc, Prof, Thaler, Josef, Prof, Bridgewater, John, MD, Petersen, Lone Nørgård, Prof, Blons, Hélène, PhD, Collette, Laurence, PhD, Van Cutsem, Eric, Prof, Rougier, Philippe, Prof, Salazar, Ramon, Prof, Bedenne, Laurent, Prof, Emile, Jean-François, Prof, Laurent-Puig, Pierre, Prof, Lepage, Come, Prof

Volltext

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 von Marchand, Marie, van Baren, Nicolas, Weynants, Patrick, Brichard, Vincent, Dréno, Brigitte, Tessier, Marie‐Hélène, Rankin, Elaine, Parmiani, Giorgio, Arienti, Flavio, Humblet, Yves, Bourlond, André, Vanwijck, Romain, Liénard, Danielle, Beauduin, Marc, Dietrich, Pierre‐Yves, Russo, Vincenzo, Kerger, Joseph, Masucci, Giuseppe, Jäger, Elke, De Greve, Jacques, Atzpodien, Jens, Brasseur, Francis, Coulie, Pierre G., van der Bruggen, Pierre, Boon, Thierry

Volltext